Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MediVas LLC
The Dutch API and materials manufacturer DSM has licensed a series of biodegradable polymers from US firm MediVas for use in drug delivery applications.
The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
- Site Specific
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule